AGM
TSHA icon

Alpine Global Management’s Taysha Gene Therapies TSHA Stock Holding History

Alpine Global Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-151,483
Closed -$339K – 456
2024
Q2 		$339K Buy
+151,483
New +$441K 0.06% 221

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Alpine Global Management's TSHA Position: Q3 2024 in Review

Alpine Global Management sold out of Taysha Gene Therapies (TSHA) in Q3 2024, closing a stake of 151,483 shares — an estimated $339K sold.

Alpine Global Management first reported a position in TSHA in Q2 2024 and held it in 1 quarter. The position peaked at $339K in Q2 2024. 119 funds tracked by Wall St. Rank hold TSHA as of Q3 2024.

  • Alpine Global Management reported no remaining Taysha Gene Therapies position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 151,483 Taysha Gene Therapies shares in Q3 2024, an estimated $339K.
  • Alpine Global Management first reported a position in Taysha Gene Therapies in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's Taysha Gene Therapies position peaked at $339K in Q2 2024.
  • 119 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.